Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work

Potential Sciences is a new AI startup using physics-based simulations to predict molecular interactions, aiming to bypass traditional lab-based drug discovery. The company has secured seed funding to develop bespoke treatments for diseases, including rare conditions.
Why it matters
AI-driven drug discovery could significantly reduce the time and cost of bringing new, personalized medicines to market.
Potential Sciences plans to build large-scale chemical datasets by using basic principles of physics to simulate interactions between atoms, then small molecules, then complex amino acids and proteins. With that data, it’s betting it can train AI models and prediction systems capable of identifying highly targeted drugs for specific diseases, bypassing costly and time-consuming lab experimentation.
“We want molecules that are never going to work in the clinic to fail fast,” Hatem Helal, Potential Science’s founder and CEO, tells WIRED. “That means having better predictors of how they will behave as they interact with human biology.”
The startup, which launched on November 5, says it has seed funding in the tens of millions of dollars from SovAI—the UK government’s AI venture capital fund—and Twin Path Ventures, among other investors. The founders declined to disclose the precise figure or valuation.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in